Pacientes com aldosteronismo primário (AP) apresentam maior risco de eventos adversos cardiovasculares, fibrilação atrial e doença renal crônica do que pacientes com hipertensão essencial.[28]Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916.
https://academic.oup.com/jcem/article/101/5/1889/2804729
http://www.ncbi.nlm.nih.gov/pubmed/26934393?tool=bestpractice.com
[66]Monticone S, D'Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50.
http://www.ncbi.nlm.nih.gov/pubmed/29129575?tool=bestpractice.com
Portanto, o diagnóstico precoce e o início do tratamento específico são essenciais para reduzir o risco de complicações. Além do controle da pressão arterial, os níveis de renina suprimidos também estão associados a desfechos cardiovasculares mais desfavoráveis.[137]Vaidya A, Hundemer GL, Nanba K, et al. Primary aldosteronism: state-of-the-art review. Am J Hypertens. 2022 Dec 8;35(12):967-88.
https://academic.oup.com/ajh/article/35/12/967/6620780
http://www.ncbi.nlm.nih.gov/pubmed/35767459?tool=bestpractice.com
Existem evidências de que a espironolactona é capaz de melhorar os efeitos adversos cardiovasculares e renais não dependentes de PA causados pelo excesso de aldosterona.[58]Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991 Jun;83(6):1849-65.
http://www.ncbi.nlm.nih.gov/pubmed/1828192?tool=bestpractice.com
[61]Rossi GP, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996 May;27(5):1039-45.
http://hyper.ahajournals.org/content/27/5/1039.full
http://www.ncbi.nlm.nih.gov/pubmed/8621194?tool=bestpractice.com
[123]Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999 Sep 2;341(10):709-17.
http://www.nejm.org/doi/full/10.1056/NEJM199909023411001#t=article
http://www.ncbi.nlm.nih.gov/pubmed/10471456?tool=bestpractice.com
[124]Zannad F, Alla F, Dousset B, et al; Rales Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation. 2000 Nov 28;102(22):2700-6.
http://circ.ahajournals.org/content/102/22/2700.full
http://www.ncbi.nlm.nih.gov/pubmed/11094035?tool=bestpractice.com
[125]Catena C, Colussi GL, Lapenna R, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007 Nov;50(5):911-8.
http://hyper.ahajournals.org/content/50/5/911.full
http://www.ncbi.nlm.nih.gov/pubmed/17893375?tool=bestpractice.com
Modificações no estilo de vida (incluindo manutenção de um peso saudável, exercício regular, evitar o excesso de álcool, restrição de sal alimentar e abandono do hábito de fumar) devem ser iniciadas em todos os pacientes. A restrição alimentar de sal também pode reduzir a dose necessária do medicamento bloqueador de aldosterona. Os pacientes devem ser examinados para diabetes ou dislipidemia com níveis de glicemia de jejum e lipídios. A prevalência de diabetes em pessoas com AP é de aproximadamente 20%; cerca do dobro da prevalência na população em geral ou em controles hipertensos correspondentes.[145]Akehi Y, Yanase T, Motonaga R, et al. High prevalence of diabetes in patients with primary aldosteronism (PA) associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than unilateral PA: a large, multicenter cohort study in Japan. Diabetes Care. 2019 May;42(5):938-45.
https://diabetesjournals.org/care/article/42/5/938/40499/High-Prevalence-of-Diabetes-in-Patients-With
http://www.ncbi.nlm.nih.gov/pubmed/31010944?tool=bestpractice.com
[146]Reincke M, Meisinger C, Holle R, et al. Is primary aldosteronism associated with diabetes mellitus? results of the German Conn's Registry. Horm Metab Res. 2010 Jun;42(6):435-9.
http://www.ncbi.nlm.nih.gov/pubmed/20119885?tool=bestpractice.com